Lu AG13909 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 81 | 先天性副腎皮質酵素欠損症 | 1 |
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 87 / 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05669950 (ClinicalTrials.gov) | December 19, 2022 | 20/12/2022 | Study of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia | A Multi-site, Open-label, Sequential-group, Multiple-ascending-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Patients With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia | Drug: Lu AG13909 | H. Lundbeck A/S | NULL | Recruiting | 18 Years | 55 Years | All | 12 | Phase 1 | United Kingdom |